Quarterly report [Sections 13 or 15(d)]

Schedule of Accounts Payable (Details)

v3.25.2
Schedule of Accounts Payable (Details) - USD ($)
Jun. 30, 2025
Dec. 31, 2024
Jun. 30, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable interest rate 100.00% 100.00%    
Total accounts payable $ 1,374,000 $ 3,853,000    
Cytovance Biologics Inc [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable $ 598,000 [1] $ 1,183,000 [1] $ 842,000 $ 3,515,000
Accounts payable interest rate [1] 44.00% 31.00%    
University of Minnesota [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable $ 432,000 $ 712,000    
Accounts payable interest rate 31.00% 18.00%    
Legal Services Firm [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable $ 1,505,000    
Accounts payable interest rate 39.00%    
Other Accounts Payable [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable interest rate 25.00% 12.00%    
Other accounts payable $ 344,000 $ 453,000    
[1] Accounts Payable to Cytovance, a related party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock. See Note 7 – Commitments and Contingencies, Significant Agreements.